Latest filings (excl ownership)
8-K
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Gilead Sciences Announces Completion of Acquisition of Cymabay
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
20 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
11 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
28 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
SC TO-T
Third party tender offer statement
23 Feb 24
SC TO-C
Information about tender offer
14 Feb 24
SC TO-C
Information about tender offer
12 Feb 24
SC TO-C
Information about tender offer
12 Feb 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
8-K
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
8-K
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
2 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Gilead Sciences Announces Third Quarter 2023 Financial Results
7 Nov 23
8-K
Entry into a Material Definitive Agreement
14 Sep 23
424B5
Prospectus supplement for primary offering
11 Sep 23
FWP
Free writing prospectus
7 Sep 23
424B5
Prospectus supplement for primary offering
7 Sep 23
8-K
Regulation FD Disclosure
16 Aug 23
S-8
Registration of securities for employees
7 Aug 23
S-3ASR
Automatic shelf registration
4 Aug 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
Gilead Sciences Announces Second Quarter 2023 Financial Results
3 Aug 23
8-K
Departure of Directors or Certain Officers
5 May 23
UPLOAD
Letter from SEC
5 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Gilead Sciences Announces First Quarter 2023 Financial Results
27 Apr 23
CORRESP
Correspondence with SEC
25 Apr 23
PX14A6G
Letter to shareholders
6 Apr 23
DEFR14A
Revised proxy
5 Apr 23
PX14A6G
Letter to shareholders
29 Mar 23
UPLOAD
Letter from SEC
29 Mar 23
Latest ownership filings
4
Deborah H Telman
26 Apr 24
SC 13G
LEAP THERAPEUTICS, INC.
19 Apr 24
3
LEAP THERAPEUTICS, INC.
19 Apr 24
SC 13G
Xilio Therapeutics, Inc.
5 Apr 24
4
Xilio Therapeutics, Inc.
3 Apr 24
3
Xilio Therapeutics, Inc.
3 Apr 24
4
Merdad Parsey
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Kevin E Lofton
29 Mar 24
4
Deborah H Telman
12 Mar 24
4
Sandra Patterson
12 Mar 24
4
Merdad Parsey
11 Mar 24
4
Daniel Patrick O'Day
11 Mar 24
4
Johanna Mercier
11 Mar 24
4
Andrew D Dickinson
11 Mar 24
4
Merdad Parsey
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
SC 13G
Kyverna Therapeutics, Inc.
20 Feb 24
4
Kyverna Therapeutics, Inc.
13 Feb 24
SC 13G/A
Allovir, Inc.
13 Feb 24
SC 13G/A
Tango Therapeutics, Inc.
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
3
Kyverna Therapeutics, Inc.
7 Feb 24
4
TED W LOVE
6 Feb 24
3
TED W LOVE
6 Feb 24
4
Merdad Parsey
2 Feb 24
4
Johanna Mercier
2 Feb 24
4
Deborah H Telman
2 Feb 24
4
Andrew D Dickinson
2 Feb 24
4
Daniel Patrick O'Day
2 Feb 24
4
Arcus Biosciences, Inc.
31 Jan 24
SC 13D/A
Arcus Biosciences, Inc.
31 Jan 24
4
Deborah H Telman
26 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
4
Andrew D Dickinson
17 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
4
Johanna Mercier
10 Jan 24
144
Notice of proposed sale of securities
9 Jan 24